COMMUNIQUÉS West-GlobeNewswire

Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference
02/11/2018
CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today announced that management will present at the Credit Suisse [...]
Obalon Announces Third Quarter 2018 Financial Results
02/11/2018
SAN DIEGO, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon [...]
Achaogen to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 8, 2018
02/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug [...]
Humanigen Announces Lenzilumab Study Results Accepted as Oral Presentation at the 2018 Annual Meeting of the American Society of Hematology (ASH)
02/11/2018
Study Demonstrates that GM-CSF Neutralization with Lenzilumab in Combination with Chimeric Antigen Receptor T (CAR-T) Cell Therapy Prevents the Onset of Cytokine Release Syndrome, Significantly Reduces the Severity of [...]
ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2018
02/11/2018
-$0.01/share for the 9 months ended September 30th MADRID, Spain and CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company [...]
Checkpoint Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
02/11/2018
NEW YORK, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and [...]
Abiomed to Present at the Stephens 2018 Investment Conference in New York, NY
02/11/2018
DANVERS, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief [...]
Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentations at 60th American Society of Hematology Annual Meeting
02/11/2018
NEW YORK, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a company focused on developing treatments for rare and life-threatening diseases, today announced that additional global longitudinal [...]
Pernix Therapeutics to Report Third Quarter 2018 Financial Results on Thursday, November 8
02/11/2018
MORRISTOWN, N.J., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the third [...]
Caladrius Biosciences to Host Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 at 4:30 p.m. ET
02/11/2018
BASKING RIDGE, N.J., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting [...]
Catalyst Biosciences Announces Presentation at the 60th American Society of Hematology Annual Meeting & Exposition
02/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology [...]
Intensity Therapeutics Raises $6.5 Million in Series B Financing
02/11/2018
Proceeds to enable advancement of lead product candidate INT230-6 into Phase 2 clinical development for solid tumors WESTPORT, Conn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc. , a clinical-stage [...]
Neos Therapeutics to Host Third Quarter 2018 Financial Results Conference Call on November 9, 2018
02/11/2018
DALLAS and FORT WORTH, Texas, , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will report third quarter 2018 financial results prior to the opening of U.S. financial [...]
Stemline Therapeutics Announces Four ELZONRIS Presentations, Including an Oral Presentation, at Upcoming ASH Meeting
02/11/2018
NEW YORK, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that [...]
IMV Inc. Announces Q3 2018 Financial Results and Investor Conference Call Details
02/11/2018
Achieved Initial Positive Data from Phase 2 Clinical Trial in DLBCL with Merck Entered into Collaboration with Merck on Phase 2 Basket Trial Across Five Indications Attained Multiple Milestones in Clinical Trial With [...]
Myriad Presents Two New Studies at the Western Section of the American Urological Association
02/11/2018
New Data Demonstrate the Clinical Performance of the Prolaris ® and myRisk ® Hereditary Cancer Genetic Tests in Men with Prostate Cancer SALT LAKE CITY, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: [...]
Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day
02/11/2018
Community focuses on elevating awareness of the burden of FCS and impact on daily living BOSTON, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., [...]
Capricor Therapeutics to Provide Corporate Update at BIO-Europe Conference on Nov. 6
02/11/2018
Presentation to Focus on Company’s Therapeutic Pipeline for Duchenne Muscular Dystrophy and other Rare Diseases LOS ANGELES, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc . (NASDAQ: CAPR) will provide a [...]
Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018
02/11/2018
FREMONT, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated [...]

Pages